Should You Buy Xtant Medical Holdings, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Xtant Medical Holdings, Inc. (XTNT) scores a robust 8.4/10 on our 32-signal Quality of Company framework. At the current market price of $0.32 and a $45M market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 7 of 8 CirclFi valuation models project upside for Xtant Medical Holdings, Inc. (XTNT) at $0.32 — the model consensus leans bullish, with a Quality Score of 8.4/10 and Value-Trap risk of 13/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Xtant Medical Holdings, Inc. (XTNT) in 2026?
What Is the Bull Case vs the Bear Case for Xtant Medical Holdings, Inc. (XTNT)?
| Bull case — $1.84 target (+476.3%) | Bear case — $0.20 target (-37.4%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Xtant Medical Holdings, Inc.'s score of 8.4/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $0.20 (-37.4%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +137.3% across 7 bullish models from the current price of $0.32. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +513.8% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $1.84 (+476.3%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously. | Industry headwind: patent expiration revenue loss represents a meaningful risk for Xtant Medical Holdings, Inc. and its Medical Devices peers. |
| Industry tailwind: orphan drug designation could provide meaningful support for Xtant Medical Holdings, Inc.'s revenue and margin trajectory in the Medical Devices space. |
How Does XTNT Compare to Its Medical Devices Peers?
Valuation data pages: CNMD · ZBH · INMD · HAE · SNN · USAQ · HYPR · ADMT · MODD · IRMD · PODD
Which Other Stocks Score Like XTNT on Quality?
Closest companies to XTNT’s Quality of Company score of 8.4/10, across all industries.
- CXM — Sprinklr, Inc. (QOC 8.4) · analysis
- ROST — Ross Stores, Inc. (QOC 8.4) · analysis
- AWX — Avalon Holdings Corporation (QOC 8.4) · analysis
- MMYT — MakeMyTrip Limited (QOC 8.4) · analysis
- AMGN — Amgen Inc. (QOC 8.4) · analysis
- OTIS — Otis Worldwide Corporation (QOC 8.4) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does XTNT Appear In?
So Is Xtant Medical Holdings, Inc. (XTNT) Worth Buying in 2026?
The convergence of 8.4/10 quality, multi-model undervaluation (7/8 bullish, +137.3% median upside), and a median fair value of $0.76 vs. $0.32 current price makes Xtant Medical Holdings, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Xtant Medical Holdings, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About XTNT Stock?
Should I buy XTNT stock right now?
Based on CirclFi's multi-model analysis, 7 of 8 models see upside for XTNT at $0.32. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 8.4/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Xtant Medical Holdings, Inc.?
Key risks include: wide model disagreement (821% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does XTNT compare to its competitors?
Among Medical Devices peers, XTNT holds a Quality Score of 8.4/10. Comparable companies include CNMD (QOC 8.5), ZBH (QOC 8.4), INMD (QOC 8.5). The relative ranking helps investors identify whether XTNT offers better fundamental quality than alternatives in the same sector.
Is XTNT a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. XTNT's Quality Score of 8.4/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy XTNT at?
CirclFi does not provide target buy prices or price alerts. However, our 8 active models produce fair value estimates ranging from $0.20 to $1.84. At $0.32, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for XTNT.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad